

Are your **MRI contrast agents** cost-effective?

Learn more about generic **Gadolinium-Based Contrast Agents**.



FRESENIUS
KABI

caring for life

AJNR

Leukoencephalopathy in normal and pathologic aging.

V L Babikian and C Kase

AJNR Am J Neuroradiol 1987, 8 (4) 734

<http://www.ajnr.org/content/8/4/734.1.citation>

This information is current as
of April 20, 2024.

reason we propose that MR should be used as the preferred initial test before the less sensitive brainstem evoked responses and visual evoked responses. As stated in our article, visual evoked responses may provide additional support for the diagnosis of MS in patients with normal MR studies. In this admittedly small series of 10 patients, no additional information was obtained from brainstem or visual evoked responses. Rather, MR detected multiple white matter lesions in twice as many patients as did evoked responses, prompting our conclusion that "the small amount of additional information derived from VERs and BAERs may not justify these expensive tests in patients with abnormal MR scans." Although MR studies are not cheap, they are sensitive. The most expensive test, in the long run, is one that provides little or no information, and that must be followed by other more sensitive studies to establish the diagnosis.

Mary K. Edwards
Martin R. Farlow
James C. Stevens

Departments of Radiology and Neurology, Indiana University
School of Medicine
Indianapolis, IN 46223

REFERENCES

1. Bartel DR, Markand ON, Kolar OJ. The diagnosis and classification of MS. *Neurology* 1983;33:611-617
2. Farlow MR, Markand ON, Edwards MK, et al. Multiple sclerosis. *Neurology* 1986;36:828-831

Leukoencephalopathy in Normal and Pathologic Aging

The article by George et al. in the July/August 1986 issue of *AJNR* [1] deserves further comment. First, by excluding patients with stroke and those with hypertension requiring more than diuretic drugs (presumably patients with more severe hypertension), the authors eliminated the population in which white matter lucency (WML) is most commonly observed [2, 3]. It is not surprising, therefore, that they did not find a significant association between WML and hypertension in their demented patients. Furthermore, their findings apply to clinically diagnosed Alzheimer's disease only. Whether WML by itself is a cause for dementia cannot be answered from their data.

Second, CT scans of patients with Alzheimer's disease have not been reported to show prominent WML [4], and the pathologic changes involve mainly the cortical and deep gray matter [5]. It seems likely that patients with Alzheimer's disease and WML on CT are misdiagnosed or suffer from an additional, possibly unrelated disorder (as illustrated in all five autopsied cases). The finding of WML in these patients should prompt reconsidering the diagnosis. Further microinfarction could possibly be prevented with careful hypertension control.

We believe WML is a nondiagnostic but potentially important CT observation, corresponding to heterogeneous pathologic features. Its significance should be determined according to the clinical situation.

V. L. Babikian
Carlos Kase
Boston University School of Medicine
Boston, MA 02118

REFERENCES

1. George AE, de Leon MJ, Gentes CI, et al. Leukoencephalopathy in normal and pathological aging: 1. CT of brain lucencies. *AJNR* 1986;7:561-566
2. Naheedy MH, Gupta SR, Young JC, et al. Periventricular white matter changes and subcortical dementia. Clinical, neuropsychological, radiological, and pathological correlation. *AJNR* 1985;6:468
3. Goto K, Ishii N, Fukasawa H. Diffuse white matter disease in the geriatric population. *Radiology* 1981;141:687-695

4. Le May M. CT changes in dementing diseases: A review. *AJNR* 1986;7:841-853
5. Perl DP, Pendlebury WW. Neuropathology of dementia. *Neurol Clin* 1986;4:355-368

Reply

We agree that white matter lucencies are commonly observed in association with stroke and hypertension, as reported by Naheedy and others. Our intent was to investigate what the implications are when lucencies are present in normal individuals and what the consequences might be for patients with Alzheimer's disease. To examine this question, we excluded patients with severe hypertension, stroke, or other neurologic conditions so as to purify the group under investigation (i.e., subjects with white matter lucencies). By using this strategy, it is true that we gave up a clear view of the role of hypertension; however, positive results are more likely to be related to the issue in question, namely what is the clinical significance of lucency in normal individuals and Alzheimer patients. For example, the frequency of gait impairment in the Alzheimer group with lucencies was increased when compared with Alzheimer patients without lucencies; the increased frequency, therefore, can be attributed to the lucency rather than to a stroke or other potentially confounding coexisting condition.

The frequency of lucencies was slightly greater in the dementia group than in normals, but not significantly so, and the severity of the lucencies was not associated with the severity of dementia. These two findings, we feel, speak against the lucency itself being a cause of dementia. Our pathologic data supported the hypothesis that the lucencies were not a part of the Alzheimer disease found but may have potentiated its dementing effects.

Dr. Babikian's statement: "Patients with Alzheimer disease and WML . . . suffer from an additional, possibly unrelated disorder" succinctly summarizes the findings in our paper. The statement "WML should prompt reconsidering the diagnosis" doesn't follow. White matter lucencies may be present in patients with Alzheimer disease as well as in cognitively normal subjects.

Ajax E. George
Mony J. de Leon
New York University Medical Center
New York, NY 10016

CT Changes in Dementing Diseases

I read with interest the paper by Dr. LeMay concerning the CT changes in dementing diseases [1]. I agree that CT is valuable not only in diagnosing space-occupying lesions but also in recognizing a large number of degenerative disorders. In a list of dementing diseases that present characteristic CT changes, progressive supranuclear palsy (PSP) should be included.

Many authors have reported and emphasized the CT findings of PSP, which are characteristic and well correlated with the main pathologic specimens of the disease [2-6]. They consist of atrophy of the mesencephalon and quadrigeminal plate with prominent perimesencephalic and quadrigeminal plate cisterns and dilatation of the aqueduct and posterior third ventricle. The usefulness of CT in PSP does not need further comment. I would like to point out the possible diagnostic usefulness of CT in the early phases of PSP when the hallmark of the disorder, namely the supranuclear ophthalmoplegia, is not yet present. The difficulties in the diagnosis of PSP when the syndrome is not yet clinically evident are well known to neurologists [7]. Pfaffenbach et al. [8] in a review of 44 cases of PSP found that 16 patients presented the supranuclear palsy 2 years after the onset of the disease and 15 patients after 3 years. This means that about